Shares of Merck & Co. (MRK) were trading lower on Tuesday, caught in a broader market slide that saw major indices dip into the red. But the big news wasn't the daily price action—it was the company formally kicking off its planned acquisition of Terns Pharmaceuticals Inc. (TERN).
Merck said it has started a cash tender offer, through a subsidiary, to buy all the outstanding shares of Terns. This follows the definitive agreement the companies announced back on March 25, 2026. The offer is straightforward: $53.00 per share in cash. The tender offer is scheduled to expire on May 4, 2026, assuming it clears the usual hurdles like getting enough shareholders to participate and securing regulatory approvals.
The broader market context isn't helping. The S&P 500 was down 0.9%, and the Healthcare sector was also in the red, off 0.5%. So Merck's dip is part of a wider trend, not necessarily a verdict on the Terns deal.
Technical Analysis
At $117.40, the stock is trading just a hair above its 20-day simple moving average (SMA)—by 0.04%, to be precise. That suggests a neutral short-term trend. It's also trading 0.1% below its 50-day SMA, which hints at some weakness in the intermediate trend.
The relative strength index (RSI) sits at 61.12, which is neutral territory—the stock isn't overbought or oversold right now. The moving average convergence divergence (MACD), however, is flashing a bullish signal. The MACD line is at 0.9163, above the signal line at 0.4374, suggesting there's some upward momentum in play.
- Key Resistance: $125.00 — This level could act as a ceiling for any upward moves.
- Key Support: $114.00 — A break below here might signal more selling pressure ahead.
Over the longer term, the stock has been a strong performer, gaining 44.67% over the last 12 months. It's currently trading near its 52-week high of $125.14, which generally indicates bullish sentiment among investors.
Sector Performance
Merck operates in the Healthcare sector, which is currently ranked 6 out of 11 sectors—a mid-tier performance. Today, the sector is down 0.49%, showing it's a challenging environment for healthcare stocks overall. Look back a bit further, and the picture gets tougher: the sector has declined 5.64% over the past 30 days and 8.83% over the last 90 days, suggesting a longer-term trend of weakness.
Despite the sector's struggles, Merck's move to acquire Terns Pharmaceuticals could represent a strategic growth opportunity. That said, the stock is currently underperforming relative to its sector by 2.36 percentage points.
For those who need a refresher: Merck makes pharmaceutical products to treat conditions across several therapeutic areas, including cardiometabolic disease, cancer, and infections. Its cancer portfolio is led by its immuno-oncology platform and Keytruda, which is a major sales driver. The company also has a substantial vaccine business, including products for pediatric diseases and Gardasil for HPV. Plus, it sells animal health drugs. Geographically, 47% of Merck's sales come from U.S. human health (pharmaceuticals and vaccines).
Earnings & Analyst Outlook
Merck is scheduled to provide its next financial update on April 30, 2026.
- EPS Estimate: -101 cents (Down from 222 cents)
- Revenue Estimate: $15.93 Billion (Up from $15.53 Billion)
- Valuation: P/E of 16.6x (Indicates fair valuation)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $122.22. Recent analyst moves include:
- JP Morgan: Overweight (Raises Target to $135.00) (April 6)
- RBC Capital: Outperform (Maintains Target to $142.00) (March 30)
- Citigroup: Neutral (Raises Target to $125.00) (March 20)
MarketDash Edge Rankings
Below is a scorecard for Merck, highlighting its strengths and weaknesses compared to the broader market:
- Value: 4.02 — Indicates a weak value proposition relative to peers.
- Growth: 60.55 — Suggests moderate growth potential.
- Quality: 61.82 — Reflects a solid quality profile.
- Momentum: 83.85 — Indicates strong momentum in the stock.
The Verdict: Merck's profile is balanced, with strong momentum but weak value, suggesting the company is focused on growth opportunities while navigating current market challenges.
Top ETF Exposure
- First Trust Morningstar Dividend Leaders Index Fund (FDL): 5.50% Weight
- VanEck Pharmaceutical ETF (PPH): 8.90% Weight
- Invesco Dow Jones Industrial Average Dividend ETF (DJD): 8.90% Weight
Significance: Because MRK carries such a heavy weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
Price Action
MRK Price Action: Merck shares were down 3.12% at $117.08 at the time of publication on Tuesday, according to market data.
.jpeg)
